The FDA granted breakthrough device designation to the Haystack MRD test, which uses ctDNA to detect residual or recurrent ...

The FDA has granted breakthrough device designation to the Haystack MRD test, a circulating tumor DNA (ctDNA) test, for use in patients with stage II colorectal cancer following surgery.

Personalis' mission, since it was founded in 2011, is to transform the active management of cancer through breakthrough ...

Myriad Genetics, Inc. MYGN recently announced that The Lancet Oncology has published a study demonstrating the performance of the company’s Precise MRD in patients with oligometastatic clear-cell ...

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced new data from an AstraZeneca phase 3 clinical trial in lung cancer (NeoADAURA). The findings ...

CEO Chad Robins highlighted a strong year for Adaptive Biotechnologies, with MRD revenue increasing by 42% year-over-year. Key drivers included a higher gapfill rate of $2,007 for the clonoSEQ test ...

Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced The Lancet Oncology published a study highlighting the performance of Myriad’s ...

MRD refers to cancer cells remaining post-treatment, undetectable by standard imaging, indicating potential recurrence risk. MRD testing methods include flow cytometry and genetic tests, offering ...

This marks the first-ever inclusion of ctDNA-MRD testing in these guidelines, representing a significant advancement in lymphoma patient care. "This milestone represents a transformative moment in ...

Minimal residual disease (MRD) has emerged as a significant marker in the treatment of multiple myeloma (MM), allowing ...

DUBLIN--(BUSINESS WIRE)--The "Minimal Residual Disease Testing Market Size, Share, Forecast, & Trends Analysis By Offering, Technology, Application Sample - Global Forecast to 2031" report has been ...